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It is unclear which maintenance treatment for bipolar disorder is superior in clinical practice. Randomized controlled head-to-head trials of
available drugs either do not exist or are inconclusive. We aimed to compare rates of monotherapy treatment failure in individuals prescribed
lithium, valproate, olanzapine or quetiapine by a population-based cohort study using electronic health records. 5,089 patients with bipolar
disorder were prescribed lithium (N51,505), valproate (N51,173) olanzapine (N51,366) or quetiapine (N51,075) as monotherapy. Treatment
failure was defined as time to stopping medication or add-on of another mood stabilizer, antipsychotic, antidepressant or benzodiazepine. In
unadjusted analyses, the duration of successful monotherapy was longest in individuals treated with lithium. Treatment failure had occurred
in 75% of those prescribed lithium by 2.05 years (95% CI: 1.63-2.51), compared to 0.76 years (95% CI: 0.64-0.84) for those prescribed quetia-
pine, 0.98 years (95% CI: 0.84-1.18) for those prescribed valproate, and 1.13 years for those prescribed olanzapine (95% CI: 1.00-1.31). Lith-
ium’s superiority remained in a propensity score matched analysis; when treatment failure was defined as stopping medication or add-on of a
mood stabilizer or antipsychotic; and when treatment failure was restricted to more than three months after commencing the study drug. Lith-
ium appears to be more successful as monotherapy maintenance treatment than valproate, olanzapine or quetiapine. Lithium is often avoid-
ed because of its side effect profile, but alternative treatments may reduce the time to being prescribed more than one drug, with potential
additive side effects of these treatments.
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Bipolar disorder is a lifelong recurrent illness with high rates
of hospitalization, suicide and comorbidity1. It is the sixth
most common cause of disability in the world, responsible for
the loss of more disability-adjusted life years than all forms of
cancer or major neurological conditions such as epilepsy and
Alzheimer’s disease2. Long-term drug treatment is often re-
quired to prevent relapse or recurrence. Even with treatment,
the proportion of people who remain in remission is low3.
A number of drug treatments are recommended for mainte-
nance in bipolar disorder. In the UK, the most commonly used
medications are lithium, valproate, olanzapine and quetia-
pine4. This reflects previous National Institute for Health and
Care Excellence (NICE) guidance on first-line monotherapy
maintenance treatment, which suggested equivalence of these
drugs5. Globally, there is a range of prescribing advice, which
includes additionally lamotrigine, carbamazepine, oxcarbaze-
pine, aripiprazole and other second generation antipsychot-
ics6-8. Recent meta-analyses and network meta-analyses have
highlighted the superiority of lithium9,10, and these results
have contributed to the change in NICE guidance in Septem-
ber 2014, where lithium is presented as first line11. However,
no randomized controlled trial (RCT) has conclusively proved
the benefit of lithium over other drugs, and there are no trials
that compare valproate vs. olanzapine, valproate vs. quetia-
pine or olanzapine vs. quetiapine directly.
The applicability of RCT results to people with bipolar dis-
order in the real world may be limited by the exclusion criteria
adopted in those trials, and by diagnostic heterogeneity, diag-
nosis or treatment rejection, and complex presentations of the
illness occurring over the life course12,13. These concerns have
been raised when considering RCTs in other areas of medicine:
applying their results to managing a lifelong illness of unpre-
dictable course is not straightforward14,15. Necessary trials are
also costly and difficult to run for sufficient periods in relation
to the time course of bipolar disorder16. Electronic health re-
cords offer an opportunity to augment RCT findings with
head-to-head comparison studies which include large num-
bers of patients, representative of real world clinical practice,
and long follow-up periods.
Using data from a large UK primary care database, The
Health Improvement Network (THIN), we aimed to compare
rates of stopping medication or add-on of another psychotro-
pic drug in individuals prescribed lithium, valproate, olanza-
pine or quetiapine as maintenance monotherapy for bipolar
disorder. This outcome represents a combination of both
effectiveness and tolerability of the study medication, and is
similar to that used in many RCTs of maintenance treatment
for bipolar disorder9,10.
METHODS
Study design and setting
This was a prospective study of primary care data collected
between January 1, 1995 and December 31, 2013. The scheme
for THIN was approved by the National Health Service South-
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East Multicentre Research Ethics Committee, and scientific
approval for this study was obtained from Cegedim Strategic
Data (CSD) Medical Research’s Scientific Review Committee.
THIN is a UK primary care database that contains anony-
mized patient information from routine clinical consultations17.
General practitioners (GPs) use Read codes, a hierarchical
coding system, to record information in THIN18. These codes
include diagnoses (which map onto ICD-10 codes), symp-
toms, examination findings, referrals, test results and infor-
mation from hospital specialists, creating a longitudinal
record for each patient19. In the UK, GPs are responsible for
issuing all drug prescriptions if treatment is ongoing, follow-
ing advice from a psychiatrist, and this information is also
available20.
At the time this cohort was extracted, THIN contained re-
cords for over 11 million people17. Patients in the database have
been shown to be broadly representative of the UK population,
and GPs contributing data have been shown to be representa-
tive in terms of consultation and prescribing statistics21,22.
Approximately 98% of the UK population is registered with a GP
practice23. The incidence rate of bipolar disorder in THIN has
been shown to be similar to other European cohorts24, and valid-
ity of severe mental illness diagnoses held in primary care has
been established25.
Participants
Patients with a diagnosis of bipolar disorder were included
if they had at least one 28-day prescription of lithium, val-
proate, olanzapine or quetiapine after January 1, 1995, or after
the date at which the GP practice met quality assurance crite-
ria for data entry (based on computer usage and mortality
recording rates)26,27. Patients were excluded if they received a
diagnosis of schizophrenia at any time. They were also exclud-
ed if they were prescribed another of the study drugs, or any
other mood stabilizer, antipsychotic, antidepressant or benzo-
diazepine at the start of follow-up, or in the month before this.
The cohort was therefore one in which the intention was to
treat with lithium, valproate, olanzapine or quetiapine mono-
therapy. Patients were censored at date of death, leaving the
GP practice or the end of the study period (December 31,
2013).
Main outcome
Patients were followed up until they stopped the study
drug, or had a mood stabilizer, an antipsychotic, an antide-
pressant or a benzodiazepine added to their treatment regi-
men. Date of first prescription was taken as the start of ex-
posure time. The end of the prescription was calculated from
the prescription length and prescribing instructions coded by
the GP.
Patients were considered to have a period of continuous
prescribing if another prescription for the same drug was
issued within three months of the predicted end date. If this
did not occur, the date of stopping the study drug was the end
date of the final prescription.
Observed pre-treatment variables for propensity score
estimation
Socio-demographic, psychiatric and physical health charac-
teristics at baseline were extracted from each patient’s elec-
tronic health record. Psychiatric and physical health problems
were considered present if referenced in the patient notes. If a
patient had multiple entries of the same (or similar) Read
codes, the start date of the condition was taken as the earliest
date of entry.
A propensity score (PS) for each individual was estimated
using variables defined a priori, based on existing re-
search28,29. The PS attempts to account for all of the covariates
that predict receiving a particular study drug29,30. The PS was
then checked by comparison of covariate balance across treat-
ments, within strata. The included variables were: gender; age
at start of treatment with the study drug; year of entry to the
cohort; ethnicity (grouped as White, Black, Asian, mixed, other,
with missing values coded as White); physical health history at
baseline (ischemic heart disease, myocardial infarction, cere-
brovascular event, hypertension, renal disease, thyroid dis-
ease, liver disease, type 2 diabetes mellitus, epilepsy, history of
alcohol dependence, history of illicit drug use); smoking status
(grouped as never-smoker, ex-smoker, current smoker); body
mass index (BMI) (grouped as healthy weight, overweight
(BMI 25 to 30), obese (BMI over 30)); mental health history at
baseline (history of anxiety symptoms, hypomania as most
proximal diagnosis code, history of depressive symptoms,
sleep disturbance, previous treatment with the study drug
before baseline, incident diagnosis of bipolar disorder); and
clustering by GP practice. These variables were selected
because they represent factors influencing prescribing choice
(such as risk factors for adverse effects with a particular
study medication)11.
Although PS estimation cannot remove all bias, it has been
postulated to also reduce confounding from unmeasured vari-
ables, because of their association with measured covari-
ates31,32. Therefore in this study, for a given PS, exposure to
lithium, valproate, olanzapine or quetiapine is presumed to
have been at random33.
Statistical analysis
Cox regression analyses were conducted comparing the
rates of stopping the study drug or add-on of another psycho-
tropic medication in the four treatment groups. Analyses were
adjusted for gender, age, ethnicity and calendar year. Time to
treatment failure was summarized by Kaplan-Meier curves.
The proportional hazards model was tested formally with ana-
lysis of Schoenfeld residuals34.
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The PS was calculated using multinomial logistic regression
using the covariates described as independent variables, with
drug treatment as the dependent variable. The PS was then
used as a linear term in a Cox regression analysis that also
included age and calendar year35. This model was shown to be
superior to stratifying on PS using Akaike information criterion
and Bayesian information criterion36, and was a more efficient
use of data than PS matching, because it uses all patients.
Analysis using PS matching was then completed. Although
matched analyses may include a non-representative sample of
patients receiving treatment, they may provide a more valid
estimate of treatment effect as they compare patients with
similar observed characteristics35,37. Pairwise matching was
performed for each patient in the valproate, olanzapine and
quetiapine groups with individuals in the lithium treated
group. Patients were matched on a one-to-one basis if their PS
was within 0.01 of each other; all other patients were dropped
from the analysis.
Supplementary analyses excluding benzodiazepine and
antidepressant add-on as a source of treatment failure were
carried out. A supplementary analysis excluding patients who
stopped the study drug or had psychotropic medication
Table 1 Characteristics of patients with bipolar disorder prescribed lithium, valproate, olanzapine or quetiapine monotherapy
Lithium Valproate Olanzapine Quetiapine
Patients 1,505 1,173 1,336 1,075
Female, N (%) 860 (57.1) 631 (53.8) 733 (54.9) 735 (68.4)
Age at entry to the cohort, median (IQR) 44.9 (35.4-58.7) 41.6 (31.4-53.7) 40.9 (31.9-52.7) 38.5 (29.3-49.8)
Total years of follow-up, median (IQR) 4.2 (1.5-8.6) 3.0 (1.1-6.3) 3.6 (1.4-6.9) 2.1 (0.9-3.9)
GP practice contacts per year of follow-up, median (IQR) 12.1 (7.1-19.7) 14.8 (8.7-23.7) 14.3 (8.8-24.6) 17.9 (11.8-26.9)
Non-White ethnic background, N (%) 44 (2.9) 50 (4.3) 65 (4.9) 35 (3.3)
Health at baseline, N (%)
Ischemic heart disease, myocardial infarction, cerebrovascular event history 76 (5.0) 80 (6.8) 58 (4.3) 41 (3.8)
Renal disease history 51 (3.4) 36 (3.1) 33 (2.5) 42 (3.9)
Thyroid disease history 161 (10.7) 89 (7.6) 89 (6.7) 75 (7.0)
Diabetes 77 (5.1) 87 (7.4) 42 (3.1) 71 (6.6)
Epilepsy 29 (1.9) 82 (7.0) 37 (2.8) 34 (3.2)
Obesity (BMI>30) 617 (41.0) 488 (41.6) 482 (36.1) 467 (43.4)
Previous anxiety symptoms 98 (6.5) 102 (8.7) 133 (10.0) 154 (14.3)
Previous alcohol dependence 7 (0.5) 3 (0.3) 12 (0.9) 7 (0.6)
Current smoker 518 (34.4) 462 (39.4) 571 (42.7) 425 (39.5)
Bipolar disorder characteristics at baseline, N (%)
Incident diagnosis 318 (19.6) 396 (34.0) 543 (41.7) 416 (40.8)
Previous depressive episode 845 (56.1) 701 (59.8) 826 (61.8) 788 (73.3)
Hypomania as most recent diagnosis 234 (15.5) 154 (13.1) 238 (17.8) 125 (11.6)
Previous record of taking study drug 936 (62.2) 507 (43.2) 463 (34.7) 328 (30.5)
GP2 general practitioner, IQR2 interquartile range, BMI2 body mass index
Table 2 Rates of treatment failure by drug
Treatment failure, hazard ratio (95% CI)
N events
Person years
at risk
Rate per 100 person
years at risk Unadjusted Model 1 Model 2 Model 3
Lithium 1,151 1,570 73.3 (65.5-81.8) 1 1 1 1
Valproate 909 777 116.9 (102.9-132.4) 1.25 (1.14- 1.37) 1.22 (1.11-1.34) 1.19 (1.09-1.31) 1.20 (1.10-1.32)
Olanzapine 977 893 109.4 (96.3-123.7) 1.19 (1.08-1.30) 1.19 (1.08-1.30) 1.16 (1.05-1.28) 1.17 (1.07-1.29)
Quetiapine 814 457 177.9 (157.9-199.8) 1.48 (1.35-1.62) 1.31 (1.19-1.44) 1.30 (1.18-1.44) 1.32 (1.20-1.45)
Model 1: adjusted for clustering by primary general practitioner (GP) practice, age, gender and calendar year
Model 2: adjusted for propensity score, clustering by GP practice, age and calendar year
Model 3: propensity score matched (pairwise matching with lithium) adjusted for clustering by GP practice, age and calendar year
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added-on within the first three months of follow-up was also
performed.
All analyses were completed using STATA 1338.
RESULTS
A total of 14,396 individuals had a diagnosis of bipolar dis-
order. Of these, 5,089 were prescribed monotherapy with one of
the study drugs at the start of cohort follow-up: lithium was pre-
scribed to 1,505 people, valproate to 1,173, olanzapine to 1,366
and quetiapine to 1,075 people. Individuals prescribed lithium
tended to be older than other groups, with more years of
follow-up data and fewer GP practice contacts during this peri-
od. They were less likely to have a previous record of depression
in their notes and less likely to be an incident case (Table 1).
In unadjusted analyses, the overall rate of treatment failure
was increased for valproate, olanzapine and quetiapine when
compared to lithium (Table 2). Treatment failure had occurred
in 75% of those prescribed lithium by 2.05 years (95% CI: 1.63-
2.51), compared to 0.76 years (95% CI: 0.64-0.84) for those pre-
scribed quetiapine, 0.98 years (95% CI: 0.84-1.18) for those
prescribed valproate, and 1.13 years for those prescribed olan-
zapine (95% CI: 1.00-1.31). The median time to treatment fail-
ure in the lithium monotherapy group was 0.28 years (95% CI:
0.23-0.35), compared to 0.17 years (95% CI: 0.14-0.21) in the
quetiapine group, 0.22 years (95% CI: 0.19-0.27) in the val-
proate group, and 0.24 years (95% CI: 0.21-0.28) in the olanza-
pine group. The differences between treatments became more
apparent the longer the duration of treatment (Figure 1).
Lithium’s superiority remained after adjustment for cluster-
ing by GP practice, age, gender, calendar year, and ethnicity.
It also remained after adjusting for PS, age and calendar year,
and after matching by PS (Table 2), with olanzapine having the
least elevated hazard ratio (HR) (1.16, 95% CI: 1.05-1.28). Com-
pared to olanzapine, quetiapine had an increased rate of
monotherapy failure (HR 1.12, 95% CI: 1.02-1.23) in the PS
adjusted model. Compared to valproate, olanzapine and que-
tiapine had similar rates of treatment failure (HR 0.97, 95% CI:
0.89-1.06 and HR 1.09, 95% CI: 0.99-1.19, respectively). The
proportional hazards assumption held for all analyses. Before
pairwise matching, PS scores were most different for lithium
(median 0.45, interquartile range, IQR 0.25-0.61) and quetia-
pine (median 0.14, IQR 0.08-0.25). After matching, the median
PS was 0.21 (IQR 0.13-0.30) for lithium and 0.14 for quetiapine
(IQR 0.08-0.25).
Individuals prescribed lithium or valproate were more likely
to require antipsychotic add-on (19.53% and 18.41%, respective-
ly) than those prescribed olanzapine or quetiapine monotherapy
(10.25% and 9.02%, respectively). Conversely, individuals pre-
scribed olanzapine and quetiapine were more likely to require
mood stabilizer add-on (14.07% and 12.56%, respectively) com-
pared to lithium and valproate (6.71% and 5.20%, respectively).
Supplementary analyses produced similar results to the pri-
mary analyses. If treatment failure was restricted to stopping
the study drug or add-on of a mood stabilizer or antipsychotic
medication, PS adjusted HRs were elevated for all drugs com-
pared to lithium (Table 3). The same was true if patients failing
in the first three months of follow-up were excluded from the
analysis (Table 3, Figure 2).
DISCUSSION
As far as we are aware, this study represents the only head-
to-head comparison of the four most common maintenance
treatments for bipolar disorder, and has the longest follow-up
Figure 1 Time to treatment failure (stopped treatment or add-on of
mood stabilizer, antipsychotic, antidepressant or benzodiazepine)
(unadjusted)
Table 3 Supplementary analyses using propensity score adjusted model
Treatment failure, hazard ratio (95% CI)
Excluding benzodiazepine
add-on
Excluding benzodiazepine
and antidepressant add-on
Excluding failures in the first
three months of treatment
Lithium 1 1 1
Valproate 1.25 (1.14-1.37) 1.18 (1.08-1.29) 1.22 (1.06-1.40)
Olanzapine 1.10 (1.00-1.22) 1.17 (1.07-1.28) 1.26 (1.09-1.45)
Quetiapine 1.25 (1.13-1.38) 1.13 (1.03-1.25) 1.20 (1.04-1.40)
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and largest cohort of any direct comparison of treatments for
bipolar disorder. RCTs making these comparisons do not exist
and are unlikely to be conducted.
The overall rate of treatment failure (represented by stopping
index medication or requiring add-on of a mood stabilizer, anti-
psychotic, antidepressant or benzodiazepine) was increased for
valproate, olanzapine and quetiapine when compared to lithi-
um. This was also true if failures within the first three months
were excluded (i.e., once the patient had been stabilized on the
prescribed drug). These results suggest that monotherapy with
lithium may be more successful than the other recommended
drugs. The rate of treatment failure was also elevated for quetia-
pine compared to olanzapine, while it was not possible to sepa-
rate the other drugs from each other.
The use of contemporaneous, representative medical re-
cords avoided the risk of potential biases relating to selection
into the study. Information bias should partially have been
avoided by the use of prescribing data as exposure: in the UK,
GPs are responsible for all ongoing prescribing within the
national health system20, which is detailed and well recorded
in THIN. However, exposure to the study drug was approxi-
mated through prescriptions issued to patients, and may not
reflect how the patient used the medication. Poor adherence
to prescribed drug regimens is a problem with all medications,
and this is particularly true if side effects are unpleasant, as
can be the case with all of the study drugs39,40. In this study,
stopping the drug will be reflected in the outcome, but erratic
adherence cannot be detected. It is possible that erratic adher-
ence is more likely for drugs other than lithium (as this is more
closely monitored through regular blood tests). This may have
contributed to lithium’s perceived superiority, but we found
that patients prescribed lithium had fewer GP contacts, and
other longitudinal cohort studies have not shown differential
adherence40.
Treatment failure was defined as stopping the study drug or
add-on of any mood stabilizer, antipsychotic, antidepressant
or benzodiazepine. It is likely that addition of a mood stabiliz-
er or antipsychotic represents more serious treatment failure
than addition of an antidepressant (which would only occur
during a depressive relapse) or a benzodiazepine (which may
be used short term to avoid a relapse). A supplementary analy-
sis excluding addition of these drugs had similar results. It
may be the case that both of these outcomes fail to capture
what is important to patients in terms of relapse, recurrence,
functioning and quality of life. However, through examining
monotherapy treatment failure, we believe we have described
a proxy for these important outcomes which captures both tol-
erability and effectiveness and highlights very common need
for adjunctive drug treatments. This outcome has also been
used in a number of RCTs of maintenance drug treatment for
bipolar disorder and therefore comparison with these results
is possible. For example, the largest trial of lithium vs. val-
proate treatment had a primary outcome of “time to new
intervention for an emerging mood episode”41.This trial found
similar results to our study (HR 1.41, 95% CI: 1.00-1.92), but
was not powered to directly compare lithium and valproate.
A limitation of interpretation of data from cohort studies is
the inability to rule out important confounding effects. We
attempted to account for confounding by indication by build-
ing a PS model that included important clinical predictors of
treatment allocation30. This included physical health variables
which may lead a clinician to avoid a certain drug because
of its side effect profile, e.g. renal disease with lithium or car-
diovascular disease with olanzapine. Characteristics such as
gender, age and BMI were also included, as valproate is contra-
indicated (though commonly prescribed) in women of child-
bearing potential5, and olanzapine has the potential to cause
rapid weight gain42. Adjusting for the GP practice should
account for physician preference for a particular drug. Once
these covariates were adjusted for, there was a similar propensi-
ty for patients to be prescribed valproate, olanzapine or quetia-
pine, with patients prescribed lithium having slightly higher
scores. Despite this, we cannot rule out the possibility that
these confounders were imperfectly adjusted for, or that other
important confounders were not included in the PS model.
Unfortunately, we were unable to separate treatment failure
relating to emergent manic (or hypomanic) episodes from
depressive episodes, and there is evidence that the study drugs
may be differentially effective in preventing a particular polari-
ty of illness9. However, an ideal “mood stabilizer” would pro-
tect against both polarities of relapse43, and this is what our
study captures. We were also unable to examine the physi-
cian’s reason for treatment initiation, and it may be that que-
tiapine’s apparent inferiority is because in some patients it is
prescribed as maintenance treatment, but for shorter term
indications (which we hoped to capture in the supplementary
analysis). There were too few patients on monotherapy with
other recommended maintenance treatments, such as lamo-
trigine or aripiprazole, to include these drugs in the analysis.
In conclusion, this study provides necessary supplementary
and complementary evidence to RCT findings for mainte-
nance treatments for bipolar disorder. In real world clinical
Figure 2 Time to treatment failure (excluding failures in the first
three months of treatment) (unadjusted)
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practice, lithium appears to be the most effective treatment to
prevent relapse or recurrence of bipolar disorder and may pro-
long the time before adjunctive prescribing is necessary. This
finding echoes the results of recent meta-analyses that suggest
lithium is superior to other drugs in protecting against both
manic and depressive relapse9,10. This is important as lithium
is often avoided because of its side effect profile44, but mono-
therapy with valproate, olanzapine or quetiapine is more likely
to fail sooner and may result in patients experiencing the addi-
tive side effects of multiple psychotropic drugs.
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